EUVIMEDEUVIMED entdecken
Validierungsstudie

Development and Validation of Claims‐Based Algorithms for Non‐Melanoma Skin Cancer in Patients With Psoriasis Using Optum Market Clarity

Huifang Liang iD, Shu Huang iD, Qiujie Jiang iD, Dongmu Zhang iD, Dianlin Guo iD, Simone P Pinheiro iD

Pharmacoepidemiology and Drug Safety · 2026-03 · 35 (3)

DOI: 10.1002/pds.70345 ↗

Kurz gefasst

Validierungsstudie in der Zeitschrift Pharmacoepidemiology and Drug Safety, online erschienen am 11.03.2026. Verfasst von Huifang Liang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Pharmacoepidemiology Center of Excellence, Global Epidemiology, Pharmacovigilance & Patient Safety, Epidemiology, and R&D Quality Assurance, AbbVie I…. Hauptthemen laut MEDLINE: Algorithms, Psoriasis, Skin Neoplasms, Non-Melanoma Skin Neoplasms. Die Arbeit nennt 21 Literaturangaben. Gefördert von: AbbVie.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Accurate identification of non‐melanoma skin cancer (NMSC) using ICD‐10 claims‐based algorithms is largely uncharacterized. This study aimed to develop and validate claim‐based algorithms for NMSC.

Methods

Adult patients with psoriasis were identified in Optum Market Clarity between Oct 2015 and Dec 2020. Eligible patients had at least 1 year of claim enrollment prior to cohort entry, linked claims‐EHRs, overlapping follow‐up periods, and no prior malignancy. Data were randomly split into the development and validation datasets. Broad NMSC encompassed narrow NMSC (basal cell carcinoma, squamous cell carcinoma, sebaceous cell carcinoma, and malignant neoplasms of the sweat glands), Merkel cell carcinoma, carcinoma in situ, Kaposi sarcoma of skin, and cutaneous T‐cell or B‐cell lymphoma. The five developed claims‐based algorithms consisted of 1+ diagnosis code (1) at any position; (2) at the primary position; (3) by a dermatologist; (4) at any position plus treatment procedure code; (5) at primary position plus treatment procedure code. NMSC cases and non‐cases were adjudicated using EHR records. Algorithms performance measures were estimated.

Results

Of 25 647 patients (mean age 51.4 ± 15.2 years, female 53.6%), 321 broad and 281 narrow NMSC patients were identified in the development dataset ( n = 12 824). Algorithm sensitivity was 89.9% (algorithm 1) and 81.9% (algorithm 2) but under 65% for algorithms 3–5 for broad NMSC. PPV ranged from 98.2% to 99.1%. Results were consistent in the validation dataset.

Conclusion

This study developed and validated high‐performing ICD10‐based algorithms for NMSC to facilitate future dermatology research using health data.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AlgorithmsPsoriasisSkin NeoplasmsNon-Melanoma Skin NeoplasmsInsurance Claim ReviewHumansFemaleMiddle AgedMaleAdultAgedInternational Classification of Diseases

Stichwörter der Autor:innen

ICD‐10‐CMalgorithmnon‐melanoma skin cancerpositive predictive valuesensitivityspecificity

Autor:innen und Institutionen

  • Pharmacoepidemiology Center of Excellence, Global Epidemiology, Pharmacovigilance & Patient Safety, Epidemiology, and R&D Quality Assurance, AbbVie Inc., North Chicago, Illinois, USA.
  • Moorestown Dermatology Associates, Moorestown, New Jersey, USA.

ORCID-Profile: Huifang Liang, Shu Huang, Qiujie Jiang, Dongmu Zhang, Dianlin Guo, Simone P Pinheiro

Förderung

  • AbbVie

Zitieren

APA

Liang, H., Huang, S., Jiang, Q., Zhang, D., Guo, D., & Pinheiro, S. P. (2026). Development and Validation of Claims‐Based Algorithms for Non‐Melanoma Skin Cancer in Patients With Psoriasis Using Optum Market Clarity. Pharmacoepidemiology and Drug Safety, 35(3). https://doi.org/10.1002/pds.70345

Vancouver

Liang H, Huang S, Jiang Q, Zhang D, Guo D, Pinheiro SP. Development and Validation of Claims‐Based Algorithms for Non‐Melanoma Skin Cancer in Patients With Psoriasis Using Optum Market Clarity. Pharmacoepidemiology and Drug Safety. 2026;35(3). doi:10.1002/pds.70345

BibTeX
@article{Liang2026,
  author = {Liang, Huifang and Huang, Shu and Jiang, Qiujie and Zhang, Dongmu and Guo, Dianlin and Pinheiro, Simone P},
  title = {Development and Validation of Claims‐Based Algorithms for Non‐Melanoma Skin Cancer in Patients With Psoriasis Using Optum Market Clarity},
  journal = {Pharmacoepidemiology and Drug Safety},
  year = {2026},
  volume = {35},
  number = {3},
  doi = {10.1002/pds.70345}
}
Kostenlos starten →